SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

10 Feb 2023 Evaluate
The revenue zoomed 5.31% to Rs. 22967.20 millions for the quarter ended December 2022 as compared to Rs. 21808.40 millions during the corresponding quarter last year.The Net Profit of the company registered a slight decline of -11.03% to Rs. 3888.90  millions from Rs. 4370.90 millions.The Operating Profit of the company witnessed a decrease to 5167.10 millions from 5355.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 22967.20 21808.40 5.31 68165.60 68235.00 -0.10 88298.10 72196.80 22.30
Other Income 607.40 632.40 -3.95 1896.90 1456.60 30.23 1998.90 1900.10 5.20
PBIDT 5167.10 5355.00 -3.51 12346.50 17563.30 -29.70 20102.50 21389.40 -6.02
Interest 226.20 72.60 211.57 646.60 248.20 160.52 379.00 429.30 -11.72
PBDT 4940.90 5282.40 -6.46 11699.90 17315.10 -32.43 19723.50 20832.30 -5.32
Depreciation 581.40 584.30 -0.50 1726.90 1639.70 5.32 2189.80 1989.30 10.08
PBT 4359.50 4698.10 -7.21 9973.00 15675.40 -36.38 17533.70 18843.00 -6.95
TAX 470.60 327.20 43.83 1176.20 1031.70 14.01 2121.20 1992.20 6.48
Deferred Tax -293.40 -481.10 -39.01 -562.70 -1682.40 -66.55 -917.00 -1326.10 -30.85
PAT 3888.90 4370.90 -11.03 8796.80 14643.70 -39.93 15412.50 16850.80 -8.54
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 22.50 24.55 -8.38 18.11 25.74 -29.63 22.77 29.63 -23.15

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×